Dlk1-Dio3 miRNA PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MUSCULAR DISEASE OR CACHEXIA COMPRISING AS ACTIVE INGREDIENT miRNA LOCATED IN Dlk1-Dio3 CLUSTER OR VARIANT THEREOF

摘要

The present invention relates to a pharmaceutical composition for the prevention or treatment of muscle disease or cachexia comprising miRNA located in the Dlk1-Dio3 cluster or a variant thereof as an active ingredient. In the present invention, it was found that the expression of miRNAs located in the Dlk1-Dio3 cluster decreases with increasing age. In particular, when overexpressing most miRNAs in fully differentiated root canal, it was confirmed that the diameter of the root canal increases. In addition, it was confirmed that cachexia is improved by inhibiting Atrogin-1 protein in a tumor-induced cachexia mouse model. Therefore, miRNA located in the Dlk1-Dio3 cluster or a variant thereof can be usefully used for the treatment and prevention of Atrogin-1 dependent muscle diseases and cachexia.